头孢吡肟治疗慢性阻塞性肺疾病急性加重期并呼吸衰竭的疗效观察

目的:观察国产头孢吡肟治疗慢性阻塞性肺疾病急性加重期(AECOPD)并呼吸衰竭的疗效及安全性。方法:96例AE-COPD并呼吸衰竭患者随机分成A组(n=48)与B组(n=48),分别给予头孢吡肟、头孢哌酮钠/他唑巴坦钠治疗。2组给药剂量均为2.0g,静脉滴注,bid,疗程7～14d。结果:A组与B组总有效率分别为82%、62%(P<0.01);A组与B组痰菌清除率分别为79.1%、45.8%(P<0.05);A组与B组不良反应发生率分别为8.3%、10.4%(P>0.05)。结论:头孢吡肟治疗AECOPD并呼吸衰竭疗效优于头孢哌酮钠/他唑巴坦钠,两者均有较好的安全性。

Clinical Efficacy of Cefepime in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Complicated with Respiratory Failure

OBJECTIVE： To observe the efficacy and safety of domestic cefepime in the treatment of patients with acute exacerbation of chronic obstructive pulmonary dliseases （AECOPD） complicated with respiratory failure. METHODS： A total of ninety - six patients with AECOPD complicated with respiratory failure were randomly assigned to receive cefepime 2.0 g bid iv gtt （Group A, n =48） or cefoperazone/sulbactam （Group B, n =48） at a dose of 2.0 g bid iv gtt for 7-14 day. RESULTS： The effective rate was 82% for Group A versus 62% for Group B（P〈0.01） . The bacterial clearance rates were 79.1% and 45.8% , respectively（P 〈 0105）, and the incidences of adverse effect were 8.3% and 10.4% , respectively（P 〉 0.05） . CONCLUSION： The efficacy of cefepime is higher than that of cefoperazone/sulbactam in the treatment of patients with AECOPD complicated with respiratory failure, but both had good safety.